LFCR vs LITS

Lifecore Biomedical, Inc. vs Lite Strategy, Inc. — Valuation Comparison 2026

LFCR

Pharmaceutical Preparations
Lifecore Biomedical, Inc.
Quality
4.9
out of 10
Value Trap
20
SAFE
Price
$5.02
Last close
Models
7/13
Active
VS

LITS

Pharmaceutical Preparations
Lite Strategy, Inc.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$1.01
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType LFCR Fair ValueLFCR Upside LITS Fair ValueLITS Upside
Bayesian DCF Intrinsic $0.34 -66.2%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $0.61 -86.0% $2.76 +151.1%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.81 +78.8%
PWERM Option-Based $5.31 +5.7% $1.09 +7.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LFCR vs LITS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LFCR vs LITS — Which Stock Is More Undervalued?

LITS scores higher with a 6.5/10 quality rating vs LFCR's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lifecore Biomedical, Inc. (LFCR) and Lite Strategy, Inc. (LITS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LFCR currently trades at $5.02 with a QOC of 4.9/10, while LITS trades at $1.01 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).